Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies.

by | Jul 3, 2024 | Clinical Trials, Ensayos Clínicos - A-03 | 0 comments

JUAN JOSÉ GÓMEZ DOBLAS – ENSAYO CLÍNICO CON MEDICAMENTOS – NEWAMSTERDAM PHARMA B.V.